What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era?

Vettenranta, Kim; Dobsinská, Veronika; Kertész, Gabriella; Svec, Peter; Buechner, Jochen; Schultz, Kirk R.

Affiliation

Vettenranta K; University of Helsinki and Children's Hospital, University of Helsinki, Helsinki, Finland.
Dobsinská V; Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Comenius University, Bratislava, Slovakia.
Kertész G; Department of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Svec P; Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases, Comenius University, Bratislava, Slovakia.
Buechner J; Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.
Schultz KR; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.

Front Pediatr ; 9: 807002, 2021.

Article in En | MEDLINE | ID: mdl-35186828

Key words

BCR-ABL-like ALL; Philadelphia chromosome; acute lymphoblastic leukaemia; graft-vs.-host disease; graft-vs.-leukaemia effect; haematopoietic stem cell transplantation; tyrosine kinase inhibitors